The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).
 
Hao-Wen Sim
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst)
 
Elizabeth Barnes
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst)
 
Zarnie Lwin
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; MSD
 
Mark Rosenthal
No Relationships to Disclose
 
Helen Wheeler
No Relationships to Disclose
 
Eng-Siew Koh
No Relationships to Disclose
 
Matthew C. Foote
No Relationships to Disclose
 
Lauren Fisher
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst)
 
Robyn Leonard
No Relationships to Disclose
 
Merryn Hall
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst)
 
John Simes
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst)
 
Mustafa Khasraw
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Lilly
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Specialised Therapeutics (Inst)
Travel, Accommodations, Expenses - Roche/Genentech